Recursion Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €213.23M +45.3% -€470.84M -6.8% -220.8% +1.2 pp N/A N/A
    (estimated) €146.72M -11.0% -€505.38M +34.7% -344.5% -1.2 pp N/A N/A
    (estimated) €164.80M +129.3% -€375.14M -20.8% -227.6% +4.3 pp N/A N/A
    (estimated) €71.86M +19.5% -€473.81M -16.6% -659.3% +2.9 pp N/A N/A
    (estimated) €60.11M +18.6% -€568.45M +42.3% -945.7% -1.6 pp N/A N/A
    €50.69M +32.0% -€399.47M +41.3% -788.0% -0.52 pp -€297.65M +25.3% -587.2% +0.32 pp
    €38.40M +12.3% -€282.64M +37.0% -736.0% -1.3 pp -€237.64M +497.5% -618.8% -5.0 pp
    €34.19M +296.8% -€206.27M +34.5% -603.4% +12 pp -€39.77M -61.1% -116.3% +11 pp
    €8.62M +193.0% -€153.42M +102.6% -1,780.7% +7.9 pp -€102.37M +207.3% -1,188.2% -0.55 pp
    €2.94M +99.5% -€75.71M +40.6% -2,574.9% +11 pp -€33.31M -27.2% -1,132.8% +20 pp
    €1.47M -€53.87M -3,654.3% -€45.78M -3,105.3%

    Notifications